XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.1
COMMITMENTS AND CONTINGENCIES (Tables)
 3 Months Ended
Mar. 31, 2025
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contingent Consideration
A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the three months ended March 31, 2025 and March 31, 2024 is as follows (in thousands):
Three Months Ended March 31, 2025Contingent Consideration Liability Related to Acquisition of:
Arkis (1)
Derma Sciences (2)
ACell (2)
Surgical Innovations Associates (SIA), Inc. (2)
Balance as of January 1, 2025
$12,968 $2,686 $3 54,000 
Payment(5,000)— — — 
Change in fair value of contingent consideration liabilities (812)50 — 600 
Balance, March 31, 20257,156 2,736 3 54,600 
Short-Term - Accrued expenses and other liabilities$3,598 $— $— $35,000 
Long-Term - Other liabilities3,558 2,736 3 19,600 
Total7,156 2,736 3 54,600 
Three Months Ended March 31, 2024Contingent Consideration Liability Related to Acquisition of:
Arkis (1)
Derma Sciences (2)
ACell (2)
Surgical Innovations Associates (SIA), Inc. (2)
Balance as of January 1, 2024
$15,755 $2,557 $300 $68,700 
Change in fair value of contingent consideration liabilities(83)39 — 500 
Balance as of March 31, 2024
$15,672 $2,596 $300 $69,200 
Short-Term - Accrued expenses and other liabilities$7,562 $— $— $29,300 
Long-Term - Other liabilities8,110 2,596 300 39,900 
Total15,672 2,596 300 69,200 
(1) Location in financial statements: Research and development
(2) Location in financial statements: Selling, general and administrative
A roll forward of the fair value of the contingent consideration liabilities, as determined by Level 3 unobservable inputs, during the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended March 31,
Dollars in thousands20252024
Balance at beginning of period$69,657 $87,312 
Change in fair value (162)456 
Payments(5,000)— 
Balance at end of period$64,495 $87,768